Passage BioPASG +2.18%30 14-Day RSI is 40.34 as of Jul. 03, 2026. GuruFocus rates PASG with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,423 Biotechnology companies, Passage Bio ranks better than 78.07% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-03), Passage Bio's 14-Day RSI is 40.34.
The industry rank for Passage Bio's 14-Day RSI or its related term are showing as below:
PASG's 14-Day RSI is ranked better than 78.07% of 1423
companies
in the Biotechnology industry
Industry Median: 49.99
vs PASG: 40.34
Passage Bio (NAS:PASG) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Passage Bio 14-Day RSI Related Terms
PASG vs CTXR, HIND, GTBP: 14-Day RSI Comparison
For the Biotechnology subindustry, Passage Bio's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Passage Bio 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Passage Bio's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Passage Bio's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Passage Bio (PASG) has a 14-Day RSI of 40.34 as of Jul. 03, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Passage Bio and its competitors. According to the industry distribution chart, Passage Bio ranks #312 out of 1423 companies in the Biotechnology industry, placing it in the top 21.9%.
Is Passage Bio's 14-Day RSI too high?
Passage Bio's current 14-Day RSI is 40.34. The Biotechnology industry median 14-Day RSI is 49.99. Passage Bio's value of 40.34 is 19.3% below this industry median. Based on the distribution chart, Passage Bio ranks #312 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Passage Bio has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Passage Bio's 14-Day RSI compare to CTXR and HIND?
According to the Biotechnology industry distribution chart, Passage Bio ranks #312 out of 1423 companies for 14-Day RSI. This places Passage Bio in the top 22% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 49.99. Passage Bio's value of 40.34 is 19.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 49.99, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Passage Bio's current 14-Day RSI of 40.34 is 19.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Passage Bio and its competitors. For the Biotechnology industry, the median 14-Day RSI is 49.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Passage Bio's current 14-Day RSI is 40.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Passage Bio stock overvalued right now?
Passage Bio (PASG) has a current 14-Day RSI of 40.34. The current 14-Day RSI is 40.34 and 19.3% below the Biotechnology industry median of 49.99. Passage Bio's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Passage Bio (PASG), the current 14-Day RSI is 40.34 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
30GF Score
Get the complete analysis for PASG
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PASG has been successfully added to your 